Zheng L, Gan LH, Yao L, Li B, Huang YQ, Zhang FB, Kuang MQ, Fang N. Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer. World J Clin Cases 2023; 11(26): 6083-6090 [PMID: 37731570 DOI: 10.12998/wjcc.v11.i26.6083]
Corresponding Author of This Article
Nian Fang, PhD, Doctor, Department of Gastroenterology, The First Hospital of Nanchang, No. 128 Xiangshan North Road, Nanchang 330008, Jiangxi Province, China. zl13870673345@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2023; 11(26): 6083-6090 Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6083
Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer
Li Zheng, Li-Hong Gan, Ling Yao, Bin Li, Ya-Qin Huang, Fu-Bao Zhang, Meng-Qi Kuang, Nian Fang
Li Zheng, Li-Hong Gan, Ling Yao, Bin Li, Ya-Qin Huang, Meng-Qi Kuang, Nian Fang, Department of Gastroenterology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China
Fu-Bao Zhang, Department of Stomatology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China
Author contributions: These authors contributed equally to this work.
Supported byJiangxi Province Major Discipline Academic and Technical Leaders Project, No. 812178084229.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of The First Hospital of Nanchang.
Informed consent statement: Participants in this study and their legal guardians provide informed written consent before the recruitment of the study.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nian Fang, PhD, Doctor, Department of Gastroenterology, The First Hospital of Nanchang, No. 128 Xiangshan North Road, Nanchang 330008, Jiangxi Province, China. zl13870673345@163.com
Received: June 20, 2023 Peer-review started: June 20, 2023 First decision: July 7, 2023 Revised: July 12, 2023 Accepted: August 11, 2023 Article in press: August 11, 2023 Published online: September 16, 2023
Core Tip
Core Tip: The prognosis of HER2-positive gastric cancer patients is generally worse; hence, there is an urgent need to explore new and effective treatments. Gastric cancer is a common malignant tumor disease in the digestive system. Cumulative data suggests that the incidence rate of gastric cancer ranks second among all malignant tumors, and the mortality rate ranks third. Furthermore, there is a rising trend in the incidence rate, which poses a serious threat to the physical and mental health of the population. The rapid development of modern medical technology has promoted the emergence of targeted therapy in clinical practice. However, due to the heterogeneous and complex nature of gastric cancer progression, its application is limited and the progress is slow.
